EMERGENT BIOSOLUTIONS INC. Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31)
EMERGENT BIOSOLUTIONS INC. (EBS) had Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) of $879.80 million as of 2018-01-01, per its 10-K filed 2020-02-25.
Discontinued › Notes
us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterestAdjustedBalance1 · last filed 2020-02-25
- 2018-01-01: Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) $879.80M.
| Period end | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest, Adjusted Balance (Deprecated 2020-01-31) |
|---|---|
| 2018-01-01 | $879.80M 10-K · filed 2020-02-25 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ENANTA PHARMACEUTICALS INC (ENTA) | United States | $0.349B | -6.72 |
| Larimar Therapeutics, Inc. (LRMR) | United States | $0.344B | -1.83 |
| Vogenx, Inc. (VOGX) | United States | $0.355B | |
| Benitec Biopharma Inc. (BNTC) | United States | $0.337B | -10.08 |
| BioAge Labs, Inc. (BIOA) | United States | $0.333B | -11.88 |
| BridgeBio Oncology Therapeutics, Inc. (BBOT) | United States | $0.320B | -3.35 |
| Evommune, Inc. (EVMN) | United States | $0.320B | -5.10 |
| Prelude Therapeutics Inc (PRLD) | United States | $0.318B | -7.01 |
| ABEONA THERAPEUTICS INC. (ABEO) | United States | $0.312B | -5.63 |
| Rezolute, Inc. (RZLT) | United States | $0.382B | -6.45 |